For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Thymosin beta-4 sulfoxide (Tβ4-SO) is a naturally occurring oxidation derivative of the parent peptide thymosin beta-4, formed when the methionine-6 residue of Tβ4 is oxidized by hydrogen peroxide (H2O2) at sites of inflammation. It is a distinct compound from its parent: oxidation attenuates Tβ4's intracellular G-actin sequestering function but substantially enhances its extracellular anti-inflammatory and immune-resolution signaling. TB4-SO is not the same compound as TB-500 (the actin-binding fragment Ac-LKKTETQ used in the peptide community) nor the same as Tβ4 itself. Evidence is limited to two key publications: the 1999 Young et al. Nature Medicine paper establishing glucocorticoid-induced monocyte production and in vitro/in vivo anti-inflammatory effects, and the 2013 Evans et al. Nature Communications paper demonstrating cardiac wound healing promotion in zebrafish, mouse, and human cell culture. No human clinical trials have been conducted.
The complete TB4-SO profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use